Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates

Castration Resistant Prostate Cancer (CRPC) Clinical Trial

Official title:
A Phase I Open-label Study to Evaluate the Effect of Multiple Doses of MDV3100 (ASP9785) on the Pharmacokinetics of Substrates for CYP2C8, CYP2C9, CYP2C19, and CYP3A4 in Patients With Castration-resistant Prostate Cancer

Status Completed

Clinical Trial Summary

A drug-drug interaction study to investigate the potential pharmacokinetic interaction between MDV3100 and a cocktail of substrates for pioglitazone (CYP2C8 substrate), S-warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), and midazolam (CYP3A4 substrate).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01911728
Study type	Interventional
Source	Astellas Pharma Inc
Contact
Status	Completed
Phase	Phase 1
Start date	July 25, 2011
Completion date	February 21, 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01911741` - A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects	Phase 1
Completed	`NCT01284920` - A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients	Phase 1/Phase 2
Completed	`NCT02669147` - A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC
Recruiting	`NCT03460977` - PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma	Phase 1